Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Clinical data presentation on use of Hemopurifier for HCV infected patients

Aethlon Medical : 16 October, 2009  (New Product)
Principal investigator of studies on the use of Aethlon’s Hemopurifier to travel to San Diego to present results at the American Society of Nephrology conference
Aethlon Medical has disclosed that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN). Dr Vijay Kher, principal investigator of the Hemopurifier studies and Director of Nephrology at the Fortis Hospital in New Delhi, India will present and discuss Hemopurifier treatment results from 10am-12pm pacific time on October 30th, 2009. The event is being held at The San Diego Convention Centre in San Diego, California.

'We are honoured that Dr Kher has been invited to travel from India to present our clinical data at the largest annual gathering of Nephrologists,' stated Aethlon Chairman and CEO, Jim Joyce. The Aethlon Hemopurifier is the first-in-class medical device able to selectively remove viruses and immunosuppressive proteins from the bloodstream. In HCV care, the device targets to improve patient cure rates as an adjunct to accelerate and enhance the performance of current and future iterations of standard of care drug therapy.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo